<DOC>
	<DOCNO>NCT01464281</DOCNO>
	<brief_summary>A Randomized , open-label , multicenter study . The patient 1-3 year NAs treatment achieve HBeAg loss HBV DNA &lt; 200IU/ml switch Pegasys 48 96 week ( 12 week period overlap NA safety reason ) . The subject randomize 2 group : Group 1 : 48-week standard treatment Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment Peginterferon alfa 2a 180µg/week . All patient follow 48 week discontinuation study medication . Note : NAs stratify LAM , ETV ADV , ratio 1:1:1 .</brief_summary>
	<brief_title>A Study Switch From Nucleotide Peginterferon Alfa-2a CHB Patients Achieving HBeAg Loss HBV DNA &lt; 200IU/ml</brief_title>
	<detailed_description>eligibility criterion : Men woman old 18 65 year chronic hepatitis B HBeAg positive treat nucleoside and/or nucleotide analogue 1-2 year partial response ( HBeAg loss HBV DNA &lt; 1000copies/ml ) .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients ontreatment NAs ( ADV , ETV LAM ) 13 year , achieve HBeAg loss screening , HBV DNA &lt; 200IU/ml least 48 week Male female patient ≥ 18 65 year age Chronic hepatitis B ( positive HBsAg least 6 month prior NA therapy start ) Compensated liver disease ( ChildPugh &lt; 6 ) Absence hepatocellular carcinoma liver image and/or alfa fetoprotein &lt; 50 ng/ml Negative urine blood pregnancy test woman childbearing potential within 24 hour first PEG IFN study medication administration Able willing provide inform consent abide requirement study Neutrophil count &lt; 1.5 x 109cells/L platelet count &lt; 90 x 109cells/L Coinfections HIV , HAV , HCV , HDV HEV Women ongoing pregnancy breast feeding , wish become pregnant study period Prolonged excessive alcohol intake ( &gt; 40g/day men &gt; 30g/day woman ) Active intravenous drug abuse History current treatment telbivudine Treatment immunomodulators ( e.g . Interferon ) less one year study enrollment Treatment immunosuppressor ( include systemic corticosteroid ) antineoplastic treatment ( include radiation therapy ) &lt; =6 month prior first dose study drug expectation treatment need time study Serum concentration ceruloplasmin alfaantitrypsin consistent increase risk metabolic disease History evidence chronic pulmonary disease associate functional limitation History severe cardiac disease History severe seizure disorder current anticonvulsivant use History thyroid disease poorly control prescribed medication . Patients elevate thyroid stimulate hormone concentration elevation antibody thyroid peroxidase clinical manifestation thyroid disease History evidence severe retinopathy History autoimmune disease presence significant level autoantibody Renal insufficiency ( creatinine clearance &lt; 50 ml/min accord Cockroft Gault equation ) , kidney transplant , hemodialysis History depression uncontrolled psychiatric disorder Subjects protect law position give consent Patients reproductive potential willing use effective method contraception . Evidence active suspect cancer history malignancy ( basocellular carcinoma insitu cervical carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>nucleoside</keyword>
	<keyword>peginterferon alfa-2a</keyword>
</DOC>